Skip to main content

Isturisa FDA Approval History

Last updated by Judith Stewart, BPharm on March 31, 2020.

FDA Approved: Yes (First approved March 6, 2020)
Brand name: Isturisa
Generic name: osilodrostat
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome

Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.

Development Timeline for Isturisa

Mar  8, 2020Approval  FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.